Eli Lilly Suddenly Pauses Its COVID-19 Antibody Drug Trial

Just six days after they said they were filing an emergency approval application for its COVID-19 monoclonal antibody drug, Eli Lilly has paused the drug’s clinical trials, citing “potential safety concerns” as the reason. October 7, 2020, Lilly touted the drug for being “effective in reducing levels of the virus that causes Covid-19 in patients, and also appears to prevent patients from visiting the emergency room or hospital,” and that it had already begun talks...

Read the Full Article for Free!

You can unsubscribe at any time and I guarantee the privacy of your email. View our privacy policy

Subscribe for FREE to the #1 Natural Health Newsletter or Login for Instant Access

Unlock censored health information that Google doesn't want you to read

Keep your privacy secure — we are one of the few websites that have banned all Google and Facebook scripts to help stop their surveillance capitalism

Get access to all of Dr. Mercola's health articles, E-books and special reports